scholarly article | Q13442814 |
P50 | author | Richard W. Joseph | Q38524195 |
P2093 | author name string | Bradley C Leibovich | |
Jeanette E Eckel-Passow | |||
John C Cheville | |||
Mansi Parasramka | |||
Alexander S Parker | |||
Kevin J Wu | |||
Daniel Serie | |||
Tracy Hilton | |||
P2860 | cites work | Rising incidence of renal cell cancer in the United States | Q46854143 |
Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes | Q47988904 | ||
Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. | Q51154107 | ||
Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables | Q73821356 | ||
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice | Q33851826 | ||
Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase | Q34188390 | ||
Innovations and challenges in renal cancer: consensus statement from the first international conference | Q35901560 | ||
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. | Q36119612 | ||
The association of topoisomerase 2α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients | Q36186309 | ||
Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer | Q36621348 | ||
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing | Q37108461 | ||
DNA topoisomerase II and its growing repertoire of biological functions. | Q37313703 | ||
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology | Q37343211 | ||
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma | Q37461830 | ||
Epidemiology of renal cell cancer | Q37901838 | ||
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors | Q39605793 | ||
External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma | Q40058539 | ||
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score | Q44231764 | ||
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma | Q44605433 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 929-935 | |
P577 | publication date | 2013-12-25 | |
P1433 | published in | European Urology | Q15763991 |
P1476 | title | Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma | |
P478 | volume | 66 |
Q47812859 | Alcohol consumption, variability in alcohol dehydrogenase genes and risk of renal cell carcinoma |
Q38861806 | Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients. |
Q36317488 | BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. |
Q37573538 | Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. |
Q37520405 | Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects |
Q33751222 | DNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma |
Q38938193 | Evaluation of NIN/RPN12 binding protein inhibits proliferation and growth in human renal cancer cells |
Q35405080 | Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma |
Q41221347 | High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma |
Q64899492 | High expression of herpes virus entry mediator is associated with poor prognosis in clear cell renal cell carcinoma. |
Q41709688 | High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma |
Q92068655 | Identification of Four Pathological Stage-Relevant Genes in Association with Progression and Prognosis in Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis |
Q90032980 | LncRNA SNHG3 promotes clear cell renal cell carcinoma proliferation and migration by upregulating TOP2A |
Q34459467 | NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells |
Q64898393 | Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma. |
Q37433431 | Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma |
Q92881600 | Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms |
Q37582692 | ZNF148 modulates TOP2A expression and cell proliferation via ceRNA regulatory mechanism in colorectal cancer. |